Innovision IPO Day 5: Issue booked 30% so far, price band cut to ₹494-519. GMP hints 4% listing pop. Apply or skip?
Analysis of this story by livemint_markets · 16 Mar 2026, 9:14 AM IST (about 2 months ago)
AI Analysis
Weak IPO demand can reflect broader investor sentiment towards new listings or specific sector valuations. A lower price band might attract some investors but also signals underlying issues.
Trading Insight
Avoid subscribing to the Innovision IPO unless a significant improvement in subscription rates or a compelling valuation emerges.
Quick check: SUNPHARMA bullish bias (-1.4% 1d), CIPLA neutral (-0.6% 1d).
Key Evidence
- •Innovision IPO extended to March 17.
- •Price band lowered to ₹494-519 per share.
- •Issue booked only 30% so far.
- •Company aims to raise ₹322.84 crore for debt reduction and working capital.
- •Risk flag: Low subscription rates
Sectors:pharma
Sources and updates
Original source: livemint_markets
Published: 16 Mar 2026, 9:14 AM IST
Last updated on Anadi News: 16 Mar 2026, 9:22 AM IST
AI-powered analysis by
Anadi Algo News